# OnCo record canstem111p (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/canstem111p/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "canstem111p", "NCT02993731" ;
  schema:name "CanStem111P"@en ;
  schema:alternateName "CanStem 111P"@en, "BBI-608 pancreatic phase 3"@en ;
  schema:description "CanStem111P is the largest first-line pancreatic cancer trial ever run, 1,134 patients, and it found that the stemness inhibitor napabucasin added nothing to nab-paclitaxel and gemcitabine; the trial was stopped for futility and its control arm is now the best description of what that chemotherapy achieves."@en ;
  schema:url <https://onco.cc/trials/canstem111p/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02993731>, <https://doi.org/10.1016/j.eclinm.2023.101897> ;
  onco:status "negative" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/napabucasin/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/> ;
  onco:companies <https://onco.cc/companies/sumitomo-pharma/> ;
  onco:terms <https://onco.cc/terms/pancreatic-failed-programmes/> ;
  onco:people <https://onco.cc/people/tanios-bekaii-saab/> .